组合免疫疗法在由MD Anderson癌症中心引领的临床试验中产生患有转移性膀胱癌的患者的响应率在26％至38％之间。
“直到最近，最近的免疫检查点治疗的批准，膀胱癌的患者患有超过30年的新治疗选择。我们很快从免疫检查点单药治疗到免疫检查点组合疗法，以改善......
Patients who’ve been successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).
MD安德森癌症中心的研究人员进行的一项研究188bet体育网址显示，被称为无性造血的白血病前突变可能预示……
